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Abstract: Blood pressure (BP) control is a critical part of managing patients with type 2 diabetes. 
Perhaps it is the single most important aspect of diabetes care, which unlike hyperglycemia and 
dyslipidemia can reduce both micro- and macrovascular complications. Hypertension is more 
prevalent in individuals with diabetes than general population, and in most cases its treatment 
requires two or more pharmacological agents (about 30% of individuals with diabetes need 3 or 
more medications to control BP). In this article we describe the key evidence that has contributed 
to our understanding that reduced BP translates into positive micro- and macrovascular out-
comes. We review the data supporting current recommendation for BP target , 130/80 mmHg. 
Two studies suggest that a lower BP goal could be even more beneficial. We also present the 
comparative benefits of various antihypertensive drugs in reducing diabetes-related micro- and 
macrovascular complications. Finally we propose an evidence-based algorithm of how to initi-
ate and titrate antihypertensive pharmacotherapy in affected individuals. Overall, achieving 
BP , 130/80 mmHg is more important than searching for the “best” antihypertensive agent 
in patients with diabetes.
Keywords: blood pressure control, treatment protocol, fixed dose combination, clinical inertia, 
adherence
Introduction
Diabetes is very prevalent and places high financial burden to our society. In the United 
States during 2009 to 2034 the number of persons with diabetes is   anticipated to increase 
from 23.7 million to 44.1 million. The relative annual cost is also expected to rise from 
$113 billion to $336 billion during the same period.1 Worldwide, 366 million individu-
als are projected to have diabetes by year 2030.2 Type 2 diabetes, the predominant 
form, comprises 90% to 95% of all cases.
Macrovascular disorders are common in affected individuals. Specifically, cardiovas-
cular disease (CVD) is 2 to 5 times more prevalent in persons with diabetes than general 
population.3–5 Importantly it is the most serious complication by contributing 70% to 
all-cause mortality in affected patients.6 In the United States, diabetes is also the leading 
cause of microvascular disorders of end stage renal disease (ESRD)7,8 and retinopathy.9
Hypertension is 1.5 to 2.0 times more common in patients with diabetes than without 
diabetes,10 and more so in females than males.11 For example, about 40% of individuals 
between ages 25 to 65 already have high blood pressure (BP) at the time of diagnosis 
of diabetes.11 This figure increases further with age.4,11 Coexistence of hypertension 
with diabetes is likely due to the confounding effect of metabolic   syndrome that often 
predates both conditions.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Hypertension is not only common but also a major cause 
of cardiovascular (CV) pathology11–14 and thus mortality 
in individuals with diabetes. It is also a direct contributor 
to microvascular complications of nephropathy7,15,16 and 
retinopathy.16–18 As described in the main text, many random-
ized clinical trials have documented that good BP control 
reduces both micro- and macrovascular complications. This 
could make hypertension the single most important determi-
nant of diabetes-related morbidity and mortality compared 
to hyperglycemia that mainly causes microvascular disease 
and dyslipidemia that mostly contributes to macrovascular 
complications.
For this review article, we searched the literature for 
clinical studies related to treatment of hypertension in type 2 
diabetes. We utilized PubMed to find trials published in 2005 
to 2010. We then used citations from identified articles to 
select landmark studies printed before 2005. For this paper 
we chose mainly randomized clinical trials with large sample 
size and long duration of follow up. We narrowed further 
our selection to original works that emphasized renal and CV 
outcomes of various antihypertensive therapies in subjects 
with type 2 diabetes.
The purpose of this article is 5-fold. First, to provide 
evidence that reducing BP is beneficial in patients with 
diabetes; second, to demonstrate that optimal BP target 
is ,130/80 mmHg; third, to show that hypertension is poorly 
controlled in clinical practice worldwide; fourth, to explain 
the rationale of choosing the right antihypertensive medica-
tions; and fifth, to provide a descriptive algorithm of how to 
initiate and titrate pharmacotherapy.
Reducing BP is beneficial
Critical evidence from 2 major trials, UKPDS18,19 and 
SHEP,20 shows that reduced BP prevents complications in 
patients with type 2 diabetes.
UKPDS 3818 was a landmark study that examined if 
decreased BP in persons with new type 2 diabetes lowered 
micro- and macrovascular complications. At study entry, 
1148 subjects with less than 3 years of diabetes and mean 
BP 164/94 mmHg were randomized into “tight” BP and 
“less-tight” BP control groups. Patients in the tight BP con-
trol group received either angiotensin converting enzyme 
inhibitor (ACEi) captopril or β-blocker atenolol to bring 
BP to ,150/85 mmHg. The less-tight BP control group 
could use medications other than ACEi or β-blocker to attain 
BP ,180/105 mmHg.
After 8.4 years of follow up, the tight BP control group 
achieved a lower BP than the less-tight BP control arm 
(∆10/∆5 mmHg), resulting in greater relative reductions 
(P , 0.05) for both micro and macrovascular complications: 
24% in any diabetes related end-points, 32% in diabetes-
related deaths, 44% in strokes, 56% in heart failure (HF) 
and 34% in retinopathy. No difference in outcomes was 
seen in patients treated with either captopril or atenolol. Of 
note, about 30% of patients in the tight BP control group 
required 3 or more antihypertensive medications to achieve 
the desired BP.
UKPDS 3919 was a 10-year observational study on the 
same group of patients who participated in the original 
UKPDS 3818 trial. It examined if reduced vascular complica-
tions obtained in the UKPDS 38 were maintained 10 years 
after the end of randomization. Subjects (N = 884) underwent 
post-trial monitoring by clinic visits for the first 5 years and 
then by questionnaires for the next 5 years. The following 
2 results were observed. The BP difference between groups, 
obtained during the original study, was lost within 2 years 
of the observational phase. More importantly, the significant 
relative reductions achieved in the tight BP control arm 
during UKPDS 3818 were not sustained 10 years later. It is 
prudent to conclude that UKPDS 3919 shows the significance 
of not only decreasing BP in patients with diabetes but also 
maintaining it indefinitely in order to keep a low incidence 
of micro- and macrovascular complications.
SHEP20 examined if a low dose thiazide diuretic   prevented 
major CV events in older patients with isolated systolic 
hypertension. At study entry, 12% of 4736 subjects had 
diabetes with mean systolic BP . 160 mmHg and diastolic 
BP , 90 mmHg. Participants were randomized into 2 groups: 
chlorthalidone 12.5 to 25 mg/day or placebo. Primary out-
come was the occurrence of fatal and nonfatal strokes, fatal 
and nonfatal myocardial infarction (MI), major CV events, 
or all-cause mortality.
After 5 years of follow up, the chlorthalidone group 
achieved a lower BP than the placebo arm (∆9.8/∆2.2 mmHg), 
resulting in greater relative reductions (P , 0.05): 34% in 
major CV events, 54% in fatal and nonfatal MIs and 56% in 
major coronary heart disease (CHD) events. Patients with 
diabetes experienced an absolute benefit twice greater than 
nondiabetic individuals. This most likely reflected the fact 
that baseline CV risk was higher in persons with diabetes.
In summary, UKPDS 38,18 UKPDS 39,19 SHEP20 and 
other studies like HDFP,12 Syst-Euro,21 HOT,22 normotensive 
ABCD16 and HOPE23 provide firm evidence that even small 
BP reductions translate to significant decrease in both micro 
and macrovascular complications in persons with type 2 
diabetes. These findings have major consequences given that Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
33
BP Control in type 2 diabetes
hypertension contributes directly to CV   pathology, which in 
turn is the most common cause of mortality in diabetic indi-
viduals.6 Therefore it is imperative that providers screen and 
treat hypertension aggressively in patients with diabetes.
Evidence for BP  
less than 130/80 mmHg
Clear evidence supports the current recommendation 
that   target BP must be ,130/80 mmHg in patients with 
diabetes.24–28 This comes primarily from results of HOT22 
and Normotensive ABCD16 clinical trials.
The HOT study examined the lowest diastolic BP that 
could have the greatest impact in reducing CV events 
in patients with hypertension. At study entry, 8% of 
18790 participants with mean BP 170/105 mmHg had 
diabetes. Subjects were randomized into 3 different treat-
ment intensities so that final diastolic BP in each group 
was #80, #85 or #90 mmHg. Treatment was intensified 
based on BP response. Primary outcome was the occurrence 
of fatal or nonfatal MI, fatal or nonfatal strokes, or deaths 
from any CV cause.
After 3.8 years of follow up, the 3 groups achieved the 
following diastolic BPs: 81.1, 83.2 and 85.2 mmHg. Impor-
tantly, among 1501 patients with diabetes, the composite 
primary outcomes occurred remarkably 51% less (P = 0.005) 
in the arm with target diastolic BP # 80 mmHg than in the 
one with target #90 mmHg. The HOT22 trial clearly dem-
onstrates the need to achieve a diastolic BP # 80 mmHg in 
patients with diabetes.
The normotensive ABCD16 trial examined if further reduc-
tion of normal BP could prevent more vascular complications 
in patients with diabetes. At the time, BP , 140/90 mmHg 
was considered normal. At study entry, 480 participants with 
type 2 diabetes and mean BP 136/84 mmHg were randomized 
into ACEi enalapril, calcium channel blocker (CCB) nisol-
dipine, or placebo arm. The goal was to lower the diastolic 
BP from baseline by 10 mmHg in the treatment groups and 
maintain it at 80 to 89 mmHg in the placebo arm.
After 5.3 years of follow up, the enalapril and nisol-
dipine groups achieved a BP 128/75 mmHg and placebo 
arm a BP 137/81 mmHg. The lower BP treatment groups 
experienced significantly less strokes (P = 0.03), retinopathy 
(P = 0.019) and progression of normoalbuminuria (P = 0.012) 
or microalbuminuria (P = 0.028) than the placebo arm. Similar 
benefits were seen between patients receiving either enalapril 
or nisoldipine.
In conclusion, results from both HOT22 and nor-
motensive ABCD16 trials have clearly established that 
BP , 130/80 mmHg is an appropriate target for treatment 
of hypertension in patients with diabetes.
Could a lower BP target be more 
optimal?
Some evidence implies that even a lower BP goal than 
130/80 mmHg could be beneficial in decreasing micro and 
macrovascular complications of type 2 diabetes. Data from 
prospective observational UKPDS 3629 study and random-
ized interventional ABCD-230 trial are suggestive of this 
possibility.
UKPDS 36 examined the relationship between systolic 
BP and rate of vascular complications in 3642 individuals 
with new diabetes and mean systolic BP 135 mmHg. Primary 
outcome was the occurrence of any diabetes-related com-
plications or all-cause mortality. After 10.5 years of follow 
up, a linear relationship was observed between systolic BP 
and complications from diabetes. Every 10 mmHg decrease 
in systolic BP was associated with significant reductions in 
final outcomes by: 12% in diabetes related complications, 
15% in diabetes-related deaths, 11% in MIs and 13% in 
microvascular complications. Remarkably, there was no 
minimal systolic BP threshold at which complication rates 
stabilized or worsened. The lowest risk was seen in subjects 
with systolic BP , 120 mmHg.
The randomized ABCD-230 trial examined if angiotensin 
receptor blocker (ARB) valsartan could prevent progression 
of normo or microalbuminuria in patients with type 2   diabetes, 
who had normal BP and kidney function. At enrollment, 
129 subjects with mean BP 126/84 mmHg were random-
ized to receive either valsartan 80 mg/day or placebo. 
After 1.9 years of follow up, the valsartan arm achieved a 
BP 118/75 mmHg and placebo group a BP 124/80 mmHg 
(P , 0.001). The primary outcome, which was the progres-
sion of albuminuria, occurred significantly less in the tight 
BP arm than in the placebo group (P = 0.007), implying that 
the relative decrease in albuminuria was a direct consequence 
of reduced BP.
However, no differences in glomerular filtration rate 
(GFR) or retinopathy were detected between groups, which 
could be explained by the short duration of the trial. The 
study outcome is important given the well known association 
of microalbuminuria with the risk of renal insufficiency31 
and CVD.32,33 For example, HOPE trial showed clearly that 
every 0.4 mg/mmol rise in urine albumin/creatinine ratio 
contributed to 5.9% increase in risk of CV events.32
In conclusion, both UKPDS 36 and ABCD-2   studies 
suggest a possible benefit in reducing BP further to a Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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  target , 120/75 mmHg in patients with diabetes. However 
longer   randomized clinical trials using various antihyper-
tensive drugs are needed to test this hypothesis rigorously. 
Such trials must also include high risk subjects with multiple 
comorbidities.
Blood pressure is uncontrolled  
in clinical practice
Although BP control is the most important variable in 
preventing micro and macrovascular complications, 
observational studies consistently show that BP target is 
not achieved in most patients with type 2 diabetes. It is 
estimated that only 2.7% to 30% of individuals reach BP 
goal , 130/80 mmHg.34–40 For example, a large analysis 
of 49,420 individuals with diabetes and hypertension, from 
24 original studies conducted in different countries between 
1990 and 2004, found that although 87% of patients were 
receiving antihypertensive therapy, only 12% had achieved 
BP target , 130/85 mmHg.38
The 2005 to 2006 National Health and Nutrition Exami-
nation Survey (NHANES) documented 29.3% control rate 
of BP among 481 individuals with diabetes.36 A recent 
observational study from the Swedish National Diabetes 
Register conducted in 4570 patients with type 2 diabetes 
and CHD found that although 94% of subjects were tak-
ing antihypertensive medications, only 23% had achieved 
BP , 130/80 mmHg. Surprisingly, it was observed that 
among the three major risk factors for diabetes-related 
complications, BP target was attained in fewer subjects than 
were glycemic and cholesterol goals: hemoglobin A1c , 7% 
and low density lipoprotein , 100 mg/dL were reached in 
52% and 63% of individuals respectively.35 The 2005–2006 
NHANES and observational study by McFarlane et al also 
found that BP was the least frequently controlled variable 
of all three major risk factors.36,37
Two important factors contribute to poor BP control 
in patients with diabetes: adherence to therapy and clini-
cal inertia. Adherence is most commonly measured by the 
medication possession ratio (MPR), which was defined origi-
nally in 2000 by Bertholet.41 Adherence to antihypertensive 
treatment was evaluated recently by a systematic review of 
53 original studies published in 2000 to 2005. Results showed 
that 12-month MPR was only 67%, indicating that patients 
were not on therapy 33% of the time over a 1-year period.42 
Although the review was performed in hypertensive indi-
viduals, adherence is expected to be even lower in patients 
with diabetes, given their tighter BP goal and need for more 
medication use.18,36,43
Adherence to treatment is challenging in all clinical 
populations. Although many barriers to therapy exist, style 
of clinician counseling can be fundamental in ensuring 
adherence. Behavior change techniques like motivational 
intervention are promising in engaging patients to face 
ambivalence to treatment, identify barriers to therapy, and 
discus treatment decisions.44,45 Future research is required 
to adapt these techniques into routine clinical practice for 
optimal results.44,46
Clinical inertia quantifies the failure of providers to 
escalate treatment in the face of the obvious need to do so.47 
The prospective study ABATe evaluated clinical inertia for 
treatment of hypertension in 1169 patients with diabetes 
from 9 Veteran Administration facilities during 2005 to 
2006.48 Although average systolic BP was .140/90 mmHg 
on 2 consecutive years – at the time of clinic visit, 51% of 
individuals did not receive intensified therapy. Treatment 
change was even less likely to occur if BP was between 
130/80 and 140/90 mmHg. In a large cross-sectional study of 
35,424 subjects with elevated BP, conducted in 2003 to 2004, 
clinical inertia for management of hypertension was 37%. 
Coexistence of diabetes in these individuals was associated 
with significantly higher rates of clinical inertia.49
Physicians’ conflicting demands of care, time constraints 
and perceived patient resistance can contribute to clinical 
inertia. Methods like registries with graphical depiction of 
BP trends can help providers identify patients with chronic 
high BP measurements.50 This could ultimately help reduce 
clinical inertia. Increasing evidence also supports the role of 
other team members in using protocol-driven antihyperten-
sive therapy to achieve optimal outcomes.44,46,51
Therapeutic options
Angiotensin converting enzyme inhibitors 
(ACei)
In this section we show key evidence from trials BENE-
DICT52, CAPPP53,54 and HOPE23 that ACEi are superior 
to other drug classes in preventing nephropathy and CVD 
in patients with diabetes. These benefits are independent 
of the BP-lowering effect, thus making ACEi ideal first-
line antihypertensive agents in individuals with type 2 
diabetes.
Renal outcomes
It is well documented that ACEi are renoprotective in persons 
with diabetes, who have either hypertension, microalbuminu-
ria or renal insufficiency.52,55–59 An important example is the 
BENEDICT52 study, in which 1204 individuals with   diabetes, Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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mean BP 150/87 and normoalbuminuria received either 
placebo, ACEi, CCB or ACEi + CCB combination therapy. 
After 3 years of follow up, BP values were similar among 
all groups (about 140/80 mmHg), yet microalbuminuria 
occurred significantly less in subjects treated with ACEi-
based therapy than in those receiving CCB or placebo.
In conclusion, BENEDICT52 and other randomized 
clinical trials, like those by Ahmad et al55 and Lewis et al56 
show clearly that ACEi reduce microalbuminuria and rate 
of nephropathy in patients with type 2 diabetes apart from 
their antihypertensive effect.
Cardiovascular outcomes
More importantly, several trials document that ACEi 
decrease diabetes-related CV complications apart from their 
antihypertensive effect. The first study to address this issue 
was CAPPP.53,54 It examined if the ACEi captopril lowers 
macrovascular outcomes more than a diuretic or β-blocker 
in patients with diastolic BP $ 100 mmHg. At study entry, 
4.9% of 10,985 subjects had diabetes. After 6.1 years of follow 
up, study groups achieved similar BP 154/89 mmHg but with 
different end-points. Patients with diabetes receiving captopril 
experienced greater significant reductions than those treated 
with a diuretic or β-blocker: 41% in combined primary out-
comes (fatal and nonfatal MI, fatal and nonfatal strokes, or CV 
deaths), 66% in nonfatal MIs and 46% in total mortality.
It is worth pointing that although CAPPP trial showed 
superiority of ACEi over β-blockers, the same benefit was 
not seen in the UKPDS 3818 study. This discrepancy could 
be explained by the fact that subjects enrolled in the UKPDS 
were recently diagnosed with diabetes and therefore of low 
baseline CV risk.
Evidence from the HOPE23 trial further supports the CV 
benefits of ACEi independently of their BP-lowering effect. 
At study entry, 3577 subjects with diabetes had mean BP 
142/80 mmHg, coronary artery disease (CAD), peripheral 
arterial disease (PAD) or stroke. Participants were random-
ized to receive either ramipril 10 mg/day or placebo. Primary 
outcome was the occurrence of MI, stroke or CVD, with 
overt nephropathy being a substudy end-point. Subjects were 
followed for 4.5 years; however, the trial was terminated 
6 months earlier due to consistent benefits of ACEi over 
placebo. The ramipril group achieved a slightly lower BP 
than the placebo arm (∆2.4/∆1.0 mmHg).
However when BP differences were adjusted, patients 
with diabetes receiving ramipril experienced greater signifi-
cant reductions than those treated with placebo: 24% in overt 
nephropathy, 22% in MI, 33% in strokes, 37% in CV deaths 
and 25% in combined CV events. After the trial ended and 
the randomization was lost, participants were monitored for 
an additional 2.6 years.60 The use of ACEi was similar in 
both groups, but patients who were previously in the ramipril 
arm experienced additional 19%, 16% and 34% relative 
reductions in MIs, revascularizations and incidence of new 
diabetes respectively.
CAPPP53,54 and HOPE23 trials have shown clearly the CV 
benefits of ACEi compared to placebo, diuretics or β-blockers. 
Positive CV outcomes of ACEi over diuretics were also 
seen in the ANBP261 study during 4.1 years of observation. 
Similarly, 3 major randomized trials; hypertensive ABCD,62 
STOP-263 and FACET,64 reveal the superiority of ACEi over 
dihydropyridine CCB in reducing macrovascular events and 
especially MI, in hypertensive subjects with diabetes. These 
results were seen over a period of 3.5 to 5 years and were 
independent of the BP-lowering effect of ACEi.62–64 Collec-
tively the above 6 studies support the use of ACEi as first-line 
therapy for hypertension in patients with type 2 diabetes.
Angiotensin receptor blockers (ARB)
Data suggests that ARB could also be first-line treatment 
of hypertension in individuals with diabetes. Over the last 
decade, several randomized clinical studies have shown 
that interruption of the renin-angiotensin system by ARB is 
equally beneficial in lowering BP and rate of diabetic neph-
ropathy. However their relative importance in preventing 
CV outcomes is rather inconsistent.
Renal outcomes
Three key randomized trials, RENAAL,65 IDNT66 and 
  Parving et al67 have established that ARB are renoprotective 
in diabetes, apart from their antihypertensive effect.
The RENAAL study compared ARB losartan with pla-
cebo in 1513 patients with diabetes, mean BP 153/82 mmHg 
and baseline serum creatinine 1.9. After 3.4 years of follow 
up, both groups achieved similar BP values, but subjects 
receiving losartan experienced 25% more reduction in serum 
creatinine doubling (P , 0.05) and 28% greater decrease in 
development of ESRD (P , 0.05) than those treated with 
placebo.
IDNT66 trial had a similar design. Subjects (N = 1715) 
with diabetes, mean BP 159/87 mmHg and baseline serum 
creatinine 1.66 were randomized into the ARB irbesartan, 
CCB amlodipine, or placebo groups. After 2.6 years of 
  follow up, the irbesartan arm experienced 23% and 20% 
more significant reductions in composite end-points of serum 
creatinine doubling, ESRD, or death from any cause than the Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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amlodipine and placebo group, respectively. Results were 
independent of the BP-lowering effects.
A third trial, by Parving et al67 compared irbesartan 
at 2 doses (150 mg/day and 300 mg/day) with placebo in 
preventing nephropathy in 590 patients with diabetes, who 
had mean BP 153/90 mmHg and normal renal function, but 
baseline microalbuminuria. After 2 years of follow up, when 
adjusted for differences in initial urinary albumin excre-
tion (UAE) and final BP values, nephropathy – defined by 
UAE . 200 µg/min or 30% rise from baseline – occurred 
significantly less in the irbesartan 150 mg/day and irbesartan 
300 mg/day groups than in the placebo arm by 39% and 
70%, respectively.
However, it is important to add that ARB might be 
harmful in a subset of patients at high risk for vascular 
complications. In the recent randomized TRANSCEND68 
trial (N = 5926), after 4.6 years of observation, telmisartan 
80 mg/day increased creatinine doubling 59% more than 
placebo, although no difference in the occurrence of dialysis 
was detected between groups. Diabetes was present in 36% 
of participants.
In conclusion, ARB are overall more effective than 
CCB and placebo in decreasing microalbuminuria and rate 
of nephropathy in persons with diabetes, independently of 
their BP-lowering effect.
Cardiovascular outcomes
There is conflicting evidence whether ARB prevent CVD 
apart from their antihypertensive effect in patients with 
diabetes.
For example, LIFE69 demonstrated that ARB losartan 
reduced CV events greater than β-blocker atenolol in indi-
viduals with diabetes. At study entry, 13% of 9193 subjects 
with diabetes, mean BP 174/98 and left ventricular hyper-
trophy (LVH) were randomized to receive either losartan or 
atenolol. After 4 years of follow up, although BP decreased 
similarly in both groups (∆30/∆17 mmHg), combined CV 
events (death, MI or stroke) and strokes occurred significantly 
less in the ARB group than in the β-blocker arm by 13% and 
25%, respectively.
Of interest, the following significant differences were 
observed in the losartan group compared to atenolol arm: 
less adverse effects, fewer cases of new-onset diabetes and 
greater decrease in LVH. In conclusion, like ACEi captopril 
in the CAPPP53, 54 trial, ARB losartan performed better than 
β-blocker in preventing CV events in patients with diabetes. 
This was independent of BP-lowering effect and likely due 
to direct reduction of the left ventricular mass.
However, there are some contrary results from trials, 
SCOPE,70 VALUE71 and TRANSCEND.72 ARB blocker 
was not superior to placebo in SCOPE (N = 4964), or to 
CCB in VALUE study (N = 15245) in reducing composite 
CV outcomes over a period of about 4 years. In both stud-
ies diabetes was present in 12% and 34% of participants, 
respectively. However, in SCOPE, the ARB did reduce 
the secondary outcome of nonfatal strokes 28% more than 
placebo (P , 0.05).
Recently, TRANSCEND72 examined the efficacy of 
telmisartan versus placebo in preventing CV events in high 
risk patients, who were intolerable to ACEi. At enrollment, 
of 5926 individuals with CAD, PAD or stroke, 36% had 
diabetes. After 4.6 years of observation, ARB therapy low-
ered BP significantly more than placebo (∆3.2/∆1.3 mmHg). 
Unexpectedly, however, telmisartan 80 mg/day did not 
reduce the composite primary outcomes of CV death, MI, 
stroke, or HF hospitalizations more than placebo.
In conclusion, the overall evidence supports the useful-
ness of ARB in decreasing the rate of nephropathy apart from 
their BP-lowering effect. However, given the inconsistent 
benefits in preventing CV outcomes compared to CCB and 
placebo, ARB could be less favorable than ACEi as first-
line agent for treatment of hypertension in type 2 diabetes 
(indirect evidence).
ACei versus ARB
In this section we show the direct evidence documenting 
equivalence between ACEi and ARB in preventing renal 
and CV outcomes; therefore, suggesting the use of ARB as 
a first-line agent. We also demonstrate that their combina-
tion is not more beneficial than each drug alone in patients 
with type 2 diabetes.
Renal outcomes
Two important randomized trials, DETAIL73 and by 
Lacourciere et al74 show that ACEi and ARB therapies are 
equally renoprotective in diabetes. DETAIL examined if 
telmisartan was equivalent to enalapril in retarding worsening 
of renal insufficiency in subjects with type 2 diabetes, mean 
BP 152/85 mmHg and early nephropathy. At study entry, 
250 participants with GFR of .90 mL/min were randomized 
into enalapril 20 mg/day or telmisartan 80 mg/day groups. 
After 5 years of follow up, no significant differences in BP 
reduction or GFR decline (primary outcome) were detected 
between the two groups.
Analogous results were seen between ACEi enalapril 
and ARB losartan in persons with diabetes in a smaller Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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  randomized trial (N = 92) by Lacourciere et al. At 1 year, 
enalapril and losartan treatments were equivalent in lowering 
BP, and delaying both the progression of albuminuria and 
GFR fall.74 In summary the smaller studies, DETAIL73 and 
by Lacourciere et al74 suggest that ACEi and ARB are equally 
renoprotective in patients with type 2 diabetes.
Cardiovascular outcomes
Equivalence between ARB and ACEi therapy in preventing 
CV events in persons with diabetes comes from two impor-
tant randomized trials, ONTARGET75 and VALIANT.76
ONTARGET compared ARB and ARB + ACEi com-
bination treatment against ACEi therapy alone. Subjects 
(N = 25,620) with mean BP 142/82 mmHg and established 
CAD, PAD, or stroke were randomized to receive either telm-
isartan, enalapril, or both. At study entry, 37% of participants 
had diabetes. Primary outcome was the occurrence of MI, 
stroke, CV death, or hospitalization from HF. After 4.6 years 
of follow up, the telmisartan and telmisartan + enalapril 
groups achieved a slightly lower BP than the enalapril arm 
(∆0.9/∆0.6 and ∆2.4/∆1.4 mmHg respectively). However, 
the small difference in BP did not translate into improved 
composite primary outcomes in those receiving either telm-
isartan or telmisartan + enalapril therapy.
Two important observations were seen in subjects treated 
with both ACEi and ARB compared to ACEi alone. First, 
the ACEi + ARB combination group experienced a 9% 
significant relative rise in composite end-points of dialysis, 
creatinine doubling or death.77 Second, the combined therapy 
caused significantly more adverse events in the form of 
hypotension, syncope and renal insufficiency than ACEi. On 
the other hand, the telmisartan and enalapril groups achieved 
similar outcomes with similar overall side effects.
Analogous results were seen in the VALIANT76 trial, 
which compared ACEi captopril versus ARB valsartan versus 
both in preventing macrovascular complications in normoten-
sive subjects with acute MI. Of 14,808 individuals, 23% had 
diabetes. After 2.6 years of follow up, although the ACEi + 
ARB group achieved a slightly lower BP than the ACEi arm 
(∆2/∆1 mmHg, P , 0.05), the primary outcome – all cause 
mortality, CV mortality, recurrent MI, or hospitalization from 
HF – occurred similarly among all three interventional groups. 
In addition, patients treated with ACEi + ARB experienced 
more hypotensive episodes than those receiving ACEi alone 
(P , 0.05), thus resulting in frequent lowering or withdrawal 
of the combined therapy with ACEi + ARB.
In conclusion, ONTARGET75 and VALIANT76 show that 
ARB and ACEi treatments are equivalent in preventing CV 
outcomes in high risk patients with diabetes. This suggests 
that ARB could be first-line antihypertensive therapy as well 
in diabetes. However, the combination of ARB with ACEi 
was nonsuperior in end-points and caused more adverse 
events than the ACEi alone. This makes the ARB + ACEi 
combined regimen undesirable for treatment of hypertension 
in persons with type 2 diabetes.
CCB, diuretics and β-blockers
Given that most patients with diabetes will require 2 or more 
drugs to treat hypertension,18,36,43 it is important to find the 
most suitable second-line therapeutic agent. This applies also 
to patients who are intolerant of ACEi or ARB. Such infor-
mation could be extrapolated from results of 4 major trials: 
ALLHAT,78 INSIGHT,79 NORDIL80 and INVEST.81
ALLHAT examined 33,357 subjects with mean BP 
146/84 mmHg and established CHD, of which 36% had dia-
betes. Participants were randomized into 4 treatment groups: 
diuretic chlorthalidone, CCB amlodipine, ACEi lisinopril or 
α-blocker doxazosin. Primary outcome was the occurrence 
of combined fatal CHD and nonfatal MI. The doxazosin arm 
was terminated early due to increased incidence of HF. After 
4.9 years of observation, the primary outcome was similar 
among all three antihypertensive drugs.
However, for secondary end-points, the following differ-
ences were seen: the incidence of new HF in the amlodipine 
group, and combined CVD in the lisinopril arm occurred 
more commonly than in the chlorthalidone group by 38% 
and 10%, respectively (P , 0.05). This was perhaps due to 
chlorthalidone causing a slightly lower, but significant, sys-
tolic BP than amlodipine and lisinopril. Similar results were 
seen in patients with and without diabetes. Overall, the three 
antihypertensive drug classes, ACEi, CCB and thiazide, were 
equivalent in decreasing combined fatal CHD and nonfatal 
MI in high risk patients with diabetes.
INSIGHT79 (N = 6321) compared the dihydropyridine 
CCB nifedipine with diuretics, and NORDIL80 (N = 10881) 
evaluated the non-dihydropyridine CCB diltiazem versus 
diuretic or β-blocker based therapies in preventing CV events 
in patients with hypertension. In both studies, diabetes was 
present in 20.6% and 6.5% of participants, respectively. 
Participants were followed for a period of 4 to 5 years. No 
major differences in final BP values or in combined primary 
outcomes of CV deaths, stroke, or MIs were seen between 
interventional groups.
INVEST81 was a shorter duration study that compared 
the efficacy of non-dihydropyridine CCB verapamil against 
β-blocker atenolol in preventing CV events in patients with Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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hypertension and CAD. Primary end-points were   occurrence 
of nonfatal MI, nonfatal stroke, or death from any cause. 
At enrollment, 28% of 22576 subjects had diabetes. After 
2.7 years of follow up, no significant differences in BP 
measurements or primary outcomes were detected between 
the two groups.
In conclusion, ALLHAT,78 INSIGHT,79 NORDIL80 
and INVEST81 show that CCB (dihydropyridine or non-
dihydropyridine), thiazide diuretic and β-blocker are overall 
equivalent in lowering BP and rate of CV events in individuals 
with diabetes. By extrapolation, one could infer that any of 
the three classes can be added to the initial ACEi or ARB 
antihypertensive therapy. For those intolerant of ACEi or 
ARB, a CCB, thiazide or β-blocker could be used as first-line 
treatment of high BP in patients with diabetes.
A case for CCB as second-line therapy
More reliable data in choosing the second-line antihy-
pertensive therapy after ACEi or ARB in patients with 
diabetes come from ACCOMPLISH82 and GUARD83 ran-
domized trials. ACCOMPLISH evaluated if ACEi + CCB 
(benazepril + amlodipine) was superior to ACEi + hydrochlo-
rothiazide (benazepril + HCTZ) combination therapy in pre-
venting CV events in subjects with mean BP 145/80 mmHg 
and established MI, CAD, previous coronary revasculariza-
tion or stroke. At study entry, 60% of 11,506 participants had 
diabetes. Primary outcome was the occurrence of CV death, 
MI, stroke, hospitalization from angina, coronary revascular-
ization, or resuscitation after sudden cardiac arrest.
The trial was terminated early at 3 years due to clear 
benefits in the benazapril + amlodipine arm: ACEi + CCB 
combination group achieved a lower BP (∆0.9/∆1.1 mmHg, 
P , 0.001) and 20% greater reduction (P , 0.001) in com-
posite primary outcomes than the ACEi + HCTZ arm. Similar 
results were noted among patients with diabetes. However, 
for renal outcomes in individuals with diabetes, secondary 
analysis revealed that serum creatinine doubling or ESRD 
occurred similarly in both interventional groups (HR = 0.78, 
P , 0.48).84
In contrary, the smaller study GUARD83 showed that 
the same ACEi + CCB combined therapy used in ACCOM-
PLISH82 could be more beneficial than ACEi + HCTZ regi-
men in preventing diabetic nephropathy. At enrollment, 332 
subjects with diabetes, albuminuria and mean BP 151/88 
mmHg received either the benazepril + amlodipine or 
benazepril + HCTZ combination therapy. After 1 year of 
follow up, individuals treated with ACEi + CCB achieved 
a lower diastolic BP (∆2 mmHg, P , 0.05) and higher 
GFR (∆11.6 mL/min, P , 0.05) than those receiving the 
ACEi + HCTZ regimen.
It is worth noting that dihydropyridine and non-
  dihydropyridine CCB seem to be equivalent in reducing albu-
minuria and BP in diabetic individuals.85 Indirect evidence 
also suggests their similarity in preventing CV outcomes in 
persons with diabetes.78–81 In conclusion, ACCOMPLISH82 
and GUARD83 suggest that a dihydropyridine CCB could be 
a better second-line agent than a diuretic thiazide in lowering 
BP and risk of CV disease in individuals with hypertension 
and type 2 diabetes. However, its relative benefit in prevent-
ing diabetic nephropathy is somewhat inconsistent.
Aldosterone antagonists, renin  
inhibitor and α-blockers
Aldosterone antagonists, renin inhibitor and α-blockers can 
also be utilized to bring BP to goal in patients with type 2 
diabetes. Unfortunately no significant comparative data of 
these agents with ACEi, ARB, CCB, diuretics or β-blockers 
are available in persons with diabetes. The one exception 
is α-blocker doxazosin, which increased the incidence of 
HF more than diuretic chlorthalidone in participants of the 
ALLHAT trial.78
Evidence suggests that aldosterone antagonists could 
be critical in treating diabetic individuals with resistant 
hypertension – defined by the use of $3 BP-lowering drugs. 
For example, in the observational study ASCOT-BPLA,86 
spironolactone 25 to 50 mg/day reduced the BP markedly by 
∆22/∆9 mmHg in 1411 subjects with refractory hypertension 
over a 1.3-year period. In another observational trial of 7 to 15 
months’   duration, spironolactone 25 to 100 mg/day lowered 
BP by ∆16/∆9 mmHg (P , 0.001) in 175 subjects with resis-
tant high BP.87 In both studies, diabetes was present in 40% 
and 33% of participants, respectively. It is worth noting that 
about 15% of individuals with type 2 diabetes and refractory 
hypertension have primary hyperaldosteronism,88 for which 
aldosterone antagonist spironolactone or eplerenone would 
be an ideal therapy.
The renin inhibitor aliskiren, the newest antihyperten-
sive drug class, could be renoprotective apart from its BP-
lowering effect in persons with diabetes. For example, in 
the AVOID89 trial, 599 subjects with type 2 diabetes, mean 
BP 135/78 mmHg and baseline macroalbuminuria – already 
treated with the ARB losartan 100 mg/day – were randomized 
to receive aliskiren 300 mg/day or placebo. After 6 months of 
follow up, the renin inhibitor reduced proteinuria 20% more 
than placebo (P , 0.001). This outcome was independent of 
the antihypertensive effect of aliskiren.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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In conclusion, aldosterone antagonists, renin inhibitor and 
α-blockers can be added to mainstream therapies of ACEi, 
ARB, CCB, diuretics or β-blockers, if necessary, to reduce 
BP to ,130/80 mmHg in patients with type 2 diabetes.
Fixed combination therapy improves  
BP control
One method to improve adherence and reduce clinical inertia 
among individuals with diabetes and hypertension is to offer 
a 2-drug fixed dose combination therapy. This is a good 
rationale since most patients will require more than one drug 
class to reduce BP to goal.18,36,43
The best evidence comes from ADVANCE90 trial, which 
examined if fixed ACEi + thiazide (perindopril + indapamide) 
treatment was superior to other antihypertensive regimens 
in lowering vascular complications in subjects (N = 11140) 
with type 2 diabetes and mean BP 145/81 mmHg. Primary 
outcome was the occurrence of combined micro- and macro-
vascular complications – defined by CV death, nonfatal MI, 
nonfatal stroke, retinopathy and nephropathy.
After 4.3 years of follow up, the fixed perindopril + inda-
pamide group experienced a lower BP (∆5.6/∆2.2 mmHg, 
P , 0.05) and less composite primary outcomes (∆9%, 
P , 0.05) than the control arm. In regard to secondary end 
points, the fixed ACEi+Thiazide group also experienced 
significantly fewer CVD and deaths from any cause than its 
counterpart by 18% and 14% respectively.
Results of two smaller randomized trials also support the 
beneficial use of fixed dose combination therapy for treatment 
of hypertension in type 2 diabetes. In the PREMIER91 study, 
481 subjects with diabetes, mean BP 158/93 mmHg and albu-
minuria were randomized to receive fixed ACEi + thiazide 
(perindopril + indapamide) therapy or ACEi (enalapril) alone. 
Medication doses were increased based on BP response. 
Primary outcome was the difference in the albumin excretion 
rate and supine BP measurements. After 12 months of fol-
low up, the fixed perindopril + indapamide group achieved 
a lower BP (∆3/∆1.5 mmHg, P , 0.05) and less urinary 
albumin excretion than the enalapril arm.
In the SHIELD92 trial, 214 individuals with diabetes and 
mean BP 156/97 mmHg were randomized to receive either 
fixed ACEi + CCB (benazepril + amlodipine) therapy or 
ACEi (enalapril) alone. Medication doses were increased 
in both groups if BP $ 130/80 mmHg. At 3 months, 63% 
of subjects in the fixed ACEi + CCB therapy group had 
achieved the BP goal compared to only 37% of those treated 
with enalapril. The difference was statistically significant 
(P = 0.002).
In summary, early initiation of 2-drug fixed dose 
  combination therapy with ACEi + CCB or thiazide improves 
BP control more than monotherapy in patients with hyperten-
sion and diabetes.
Recommendations
Hypertension is not only the main contributor of increased 
CV morbidity and mortality in patients with type 2 diabetes, 
but also the least controlled variable compared to hyperg-
lycemia and dyslipidemia risk factors.35–37 This calls for an 
aggressive approach in reducing BP under 130/80 mmHg in 
all individuals with diabetes. Perhaps a lower target might be 
considered in the future.29,30 Similar to guidelines by several 
major organizations,24–28 we recommend that if BP is persis-
tently $130/80 mmHg, then life-style intervention should be 
initiated. However, if BP $ 140/90 mmHg, pharmacotherapy 
must be started as well.
Life-style changes that reduce BP93 are low sodium 
diet , 1.5 g/day,94 increased potassium intake .4.7 g/day, 
BMI , 25 kg/m2, weight loss by .4.5 to 5.0 kg,95,96 increased 
intake of fruits and vegetables (8 to 10 servings/day), 
decreased consumption of dairy products that are rich in 
fat (2 to 3 servings/day), avoidance of excessive alcohol 
use (#2 drinks/day/men and #1 drink/day/women) and 
increased physical activity.96,97 Studies in patients without 
diabetes have shown that these measures are equivalent to 
drug monotherapy for mild hypertension.94 But unlike medi-
cation monotherapy, life-style interventions in the form of 
exercise and weight loss could help control other aspects of 
diabetes such as hyperglycemia and dyslipidemia.
If life-style changes are unsuccessful or BP $ 140/ 
90 mmHg then pharmacotherapy should be added imme-
diately. Beta-blocker must be given to all patients with estab-
lished CAD or MI.98 In Figure 1 we present 2 different protocols 
based on initial BP value. In the first, when BP is 130/80 to 
140/90 mmHg, we advise first-line monotherapy with either an 
ACEi or ARB, depending on availability, cost and tolerability. 
Equivalence of ARB with ACEi was documented in the trials 
DETAIL,73 ONTARGET75 and VALIANT.76
In the second protocol, when BP is $ 140/90 mmHg, we 
recommend starting a low-dose fixed combination regimen 
containing either ACEi or ARB. Here we also consider patient 
adherence, clinical inertia and the fact that most individuals 
will require 2 or more drugs to control their hypertension. 
Early initiation of combined therapy is increasingly recom-
mended for glucose management as well.99 Based on indirect 
evidence from SCOPE,70 VALUE,71 and TRANSCEND,72 
one could favor treatment with ACEi over ARB. Given the Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Persistent
BP ¥ 130/80 mmHg  
Initiate life-style
modifications in all patients     
β-blocker in all individuals with
established CAD or MI
   
   
BP ¥ 140/90 mmHg
Start fixed combination therapy
BP 130/80–140/90 mmHg
Start monotherapy
ACEi/ARB + CCB   ACEi/ARB + Diuretic ACEi ARB
CCB  
Thiazide (GFR > 30 mL/min)
Loop diuretic (GFR § 30 mL/min) CCB   Thiazide (GFR > 30 mL/min)
Loop diuretic (GFR § 30 mL/min)
β-blocker
Aldosterone antagonist
Renin inhibitor
α-blocker
OR OR
OR/AND
consider work up for secondary causes of HTNa
Figure 1 Algorithm for treatment of hypertension in inividuals with diabetes. Maximize dose before starting the next drug.
First line = ACei or ARB (equivalence seen in DeTAIL73 ONTARGeT75 and vALIANT76).
•  Both reduce microalbuminuria and rate of nephropathy independently of their antihypertensive effect.
• ACei preferred over ARB (indirect evidence for cardiovascular outcomes; SCOPe,70 vALUe71 and TRANSCeND72).
•  Recommend against concomitant use of ARB with ACei (ONTARGeT75 and vALIANT76).
Second line = CCB or diuretic
•  Dihydropyridine CCB favored over diuretic (ACCOMPLISH82 and GUARD83) or in the presence of electrolyte anomalies.
•  Diuretic preferred in heart failure or edematous conditions.
•  Loop diuretic recommended if GFR # 30 mL/min due to marked state of fluid overload.
•  If needed, CCB and diuretic can be combined.
Third line = β-blocker, primarily due to side effect profile. However, it is indicated in all patients with established CAD and MI.
Fourth line = Aldosterone antagonist (ASCOT-BPLA86).
Fifth line = Renin inhibitor or α-blocker, not enough comparative data from clinical trials for clear recommendation.
Peripheral α-blocker, due to orthostatic hypotension and results of ALLHAT.78 It could be used earlier in patients with symptomatic BPH.
arenal artery stenosis, hyperaldosteronism, Cushing’s syndrome or pheochromocytoma.
Abbreviations: BP, blood pressure; ACei, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CAD, coronary 
artery disease; MI, myocardial infarction; HTN, hypertension; GFR, glomerular filtration rate; BPH, benign prostate hyperplasia.
results of   ONTARGET75 and VALIANT,76 we advise against 
concomitant use of ACEi with ARB, since together they 
cause significantly higher rates of adverse events without 
additional benefits.
In both protocols, for second-line therapy we suggest using 
dihydropyridine CCB over diuretics, based on outcomes from 
ACCOMPLISH82 and GUARD.83 The choice would also 
depend on relative contraindications of each drug class. For 
example, a CCB is favored over a thiazide in an individual with 
electrolyte anomalies but less so in someone who suffers from 
HF or edematous conditions. A loop diuretic is recommended 
over a thiazide if GFR # 30 mL/min due to patients’ state of 
fluid overload. The dose of medications must be increased or 
maximized based on BP response. If BP is still uncontrolled then 
we recommend adding either a CCB or diuretic, whichever is 
not part of the current combination therapy.
If BP goal is not achieved, we suggest adding a β-blocker. 
We chose β-blockers to be third-line agents primarily due to 
poor side effect profile of bradycardia and worsening of insulin 
resistance,100,101 although UKPDS,18 NORDIL80 and INVEST81 
clearly show their equivalence to ACEi and CCB. At this 
point we also consider screening for secondary causes of 
hypertension like renal artery stenosis, hyperaldosteronism,88 
Cushing’s syndrome or pheochromocytoma.
As a fourth-line therapy, we choose aldosterone 
antagonists due to their BP-lowering potency, revealed in 
the ASCOT-BPLA86 trial. Finally, the renin inhibitors and 
α-blockers can also be utilized, if necessary, to control BP Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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in persons with diabetes. We advise peripheral α-blockers 
to be a last-line therapeutic option based on results of ALL-
HAT78 and their propensity to cause orthostatic hypotension 
– although they could be used earlier in someone with benign 
prostate hyperplasia.
In conclusion, hypertension continues to be a key deter-
minant of morbidity and mortality in type 2 diabetes. Despite 
clear evidence for a BP goal , 130/80 mmHg, most patients 
do not achieve optimal results. Early initiation of fixed-dose 
combination therapy and aggressive titration of medications 
can improve patient adherence, reduce clinical inertia and 
bring BP to target, thereby reducing both micro- and mac-
rovascular complications in individuals with diabetes.
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